查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1991503

全球皮下給藥裝置市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Subcutaneous Drug Delivery Devices Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2034 年，皮下藥物輸送裝置市場規模將達到 837.3 億美元，高於 2025 年的 416.4 億美元，預計從 2026 年到 2034 年的複合年成長率將達到 8.07%。

隨著醫療專業人員擴大採用更便利、更人性化的治療方法，全球皮下給藥裝置市場正顯著成長。這些裝置將藥物輸送到皮下，使其緩慢吸收進入血液。它們廣泛應用於糖尿病、自體免疫疾病和荷爾蒙失調等慢性疾病的治療。患者對自我給藥療法的日益偏好是推動市場擴張的主要因素。

市場成長主要受需要長期服藥的慢性病盛行率上升的推動。病人和醫護人員更傾向於使用皮下給藥裝置，因為它們可以減少頻繁就醫的次數，簡化治療流程。醫療設備技術的進步提高了這些裝置的精準度、安全性和易用性，使其更適合居家照護。

隨著製藥公司不斷研發需要專用給藥系統的生物製藥，皮下給藥裝置市場仍前景廣闊。穿戴式注射器和智慧給藥裝置的創新有望進一步提高患者的治療依從性。醫療保健服務的普及和居家醫療解決方案的日益普及預計將推動市場持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球皮下給藥裝置市場：依產品類型分類

  • 市場分析、洞察與預測
  • 預填充式注射器
  • 自動噴油器
  • 穿戴式注射器
  • 其他

第5章 全球皮下給藥裝置市場：依應用領域分類

  • 市場分析、洞察與預測
  • 糖尿病
  • 腫瘤學
  • 自體免疫疾病
  • 其他

第6章 全球皮下給藥裝置市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 診所
  • 居家醫療環境
  • 其他

第7章 全球皮下給藥裝置市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球皮下給藥裝置市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Johnson & Johnson
    • Sanofi SA
    • Pfizer Inc
    • Abbott Laboratories
    • GlaxoSmithKline Plc
    • Bayer AG
    • Novartis AG
    • Merck & Co. Inc
    • F. Hoffmann-La Roche Ltd
    • Novo Nordisk A/S
    • Medtronic Plc
    • Becton
    • Dickinson And Company（BD）
    • Insulet Corporation
    • AstraZeneca Plc
    • Amgen Inc
簡介目錄
Product Code: VMR11214301

The Subcutaneous Drug Delivery Devices Market size is expected to reach USD 83.73 Billion in 2034 from USD 41.64 Billion (2025) growing at a CAGR of 8.07% during 2026-2034.

The global subcutaneous drug delivery devices market has grown significantly as healthcare providers increasingly adopt convenient and patient-friendly treatment methods. These devices deliver medications beneath the skin, allowing drugs to be absorbed slowly into the bloodstream. They are widely used for managing chronic conditions such as diabetes, autoimmune diseases, and hormonal disorders. The increasing preference for self-administration therapies has supported the expansion of this market.

Market growth is driven by the rising prevalence of chronic diseases that require long-term medication. Patients and healthcare providers favor subcutaneous delivery devices because they reduce the need for frequent hospital visits and simplify treatment routines. Advances in medical device technology have also improved device accuracy, safety, and ease of use, making them suitable for home-based care.

The future outlook for the subcutaneous drug delivery devices market remains promising as pharmaceutical companies continue to develop biologic drugs that require specialized delivery systems. Innovations in wearable injectors and smart drug delivery devices may further improve patient adherence to treatment. Expanding healthcare access and increasing adoption of home healthcare solutions are expected to drive continued market growth.

MARKET SEGMENTATION

By Product Type

  • Prefilled Syringes
  • Autoinjectors
  • Wearable Injectors
  • Others

By Application

  • Diabetes
  • Oncology
  • Autoimmune Diseases
  • Others

By End-User

  • Hospitals
  • Clinics
  • Home Care Settings
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Johnson Johnson, Sanofi SA, Pfizer Inc, Abbott Laboratories, GlaxoSmithKline plc, Bayer AG, Novartis AG, Merck Co Inc, F HoffmannLa Roche Ltd, Novo Nordisk AS, Medtronic plc, Becton, Dickinson and Company BD, Insulet Corporation, AstraZeneca plc, Amgen Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product Type
  • 4.2. Prefilled Syringes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Autoinjectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Wearable Injectors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY END-USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End-user
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Home Care Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Product Type
    • 8.2.2 By Application
    • 8.2.3 By End-user
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Product Type
    • 8.3.2 By Application
    • 8.3.3 By End-user
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Product Type
    • 8.4.2 By Application
    • 8.4.3 By End-user
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Product Type
    • 8.5.2 By Application
    • 8.5.3 By End-user
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Product Type
    • 8.6.2 By Application
    • 8.6.3 By End-user
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL SUBCUTANEOUS DRUG DELIVERY DEVICES INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Johnson & Johnson
    • 10.2.2 Sanofi S.A
    • 10.2.3 Pfizer Inc
    • 10.2.4 Abbott Laboratories
    • 10.2.5 GlaxoSmithKline Plc
    • 10.2.6 Bayer AG
    • 10.2.7 Novartis AG
    • 10.2.8 Merck & Co. Inc
    • 10.2.9 F. Hoffmann-La Roche Ltd
    • 10.2.10 Novo Nordisk A/S
    • 10.2.11 Medtronic Plc
    • 10.2.12 Becton
    • 10.2.13 Dickinson And Company (BD)
    • 10.2.14 Insulet Corporation
    • 10.2.15 AstraZeneca Plc
    • 10.2.16 Amgen Inc